
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is in a challenging environment, with unpredictable and potentially costly regulatory changes and state-specific regulations. However, with operations in only one segment and revenue derived from a diverse range of services, the company is well-positioned for sustainable growth and increased profitability. Upcoming financial results are expected to show 9% revenue growth, and the company is investing in expansions and new product launches, including a new cancer test and additional indications for an existing test, which could drive further revenue and margin expansion. In addition to the usual risks associated with small-cap healthcare investments, there are specific risks involving integrating acquisitions, regulatory and reimbursement changes, new technologies, and competition. The company recently reported a modest earnings beat and raise, with particular strength in NGS and improved margins, and plans to continue focusing on these growing areas in the future.
Bears say
NeoGenomics is a company that provides oncology diagnostic testing and consultative services, and while they have recently received coverage for their PanTracer LBx test and anticipate modest revenue increase for the year, there are concerns about competition in the diagnostics industry and the potential for new technologies to disrupt their business. Despite steady performance and potential growth opportunities with new product launches and expansions into different markets, there is still a risk that this company may not be able to maintain a strong competitive edge in the long-term. Additionally, establishing materiality is a crucial factor in evaluating the company's ESG performance, and it is important to consider how factors may change over time in this evolving industry.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares